<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01083147</url>
  </required_header>
  <id_info>
    <org_study_id>ForeseeHome-US3</org_study_id>
    <nct_id>NCT01083147</nct_id>
  </id_info>
  <brief_title>Age-Related Macular Degeneration (AMD) - Beta Study Telemedicine Assessment</brief_title>
  <acronym>AMD</acronym>
  <official_title>Age-Related Macular Degeneration (AMD) - Beta Study Telemedicine Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Notal Vision Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Notal Vision Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the compliance of the Foresee Home device in
      intermediate AMD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized cohort, multi-center study. The eligible subjects will be asked to
      use the FORESEE HOME device daily and the tests results will be automatically transmitted to
      the Data Monitor Center for analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Subject compliance with Foresee HomeTM device</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the Telemedicine infrastructure</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Dry AMD</arm_group_label>
    <description>subjects diagnosed as intermediate AMD in at least one eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FORESEE HOME</intervention_name>
    <description>Home Monitoring</description>
    <arm_group_label>Dry AMD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        intermediate AMD
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who successfully completed participation in ForeseeHome-US2 study

          -  Patients with ability to comprehend and sign the informed consent/authorization

        Exclusion Criteria:

          -  Subjects who failed to complete participation in ForeseeHome-US2 study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Roth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vitreos retina center - NJ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vitreos retina center</name>
      <address>
        <city>Tom's river</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2010</study_first_submitted>
  <study_first_submitted_qc>March 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2010</study_first_posted>
  <last_update_submitted>September 22, 2010</last_update_submitted>
  <last_update_submitted_qc>September 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Osnat Ehrman/Clinical manager</name_title>
    <organization>Notal Vision</organization>
  </responsible_party>
  <keyword>Intermediate AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

